 | |||||||||
 |  |  |  | ||||||
Kelowna, BC, Canada – February 25, 2025 – TheNewswire - Allied Corp. ("Allied" or the “Company”) is pleased to announce key leadership appointments as the Company moves to an exciting phase of growth with a focus on execution of established commercial contracts, within the expanding global medical cannabis market. The newly appointed management team and directors bring deep knowledge in pharmaceutical compliance, a strong expertise in operations and execution, and a track record of global market expansion within regulated industries.
KEY APPOINTMENTS :
-
Jim Smeeding – Chairman of the Board
A long-standing Board member, Jim is a Healthcare and Pharmacy executive with 45+ years experience in hospital pharmacy, managed care services and clinical services design. An entrepreneur himself, he has successfully built and led several pharmaceutical companies from funding to sale and advises major pharma and medical device firms. A founder of the Center for Pharmacoeconomic Studies at the University of Texas College Of Pharmacy, Jim also served as an Executive Director of the National Association of Specialty Pharmacy (NASP).
-
Simon Langelier – Director
A seasoned multinational executive and board member, Simon has 40+ years experience in cannabis, tobacco and consumer goods. 30+ years of leadership experience at Philip Morris International (PMI), where he led market expansion, M&A and operational restructuring across Europe, Asia, the Middle East and Africa. Among other positions at PMI, he was Managing Director for Colombia, President EEMA and President Eastern Asia. Simon also served on the Board of Imperial Brands. His expertise in strategy and expansion across global markets in highly regulated industries will be invaluable for the execution of Allied’s next phase of growth.
-
Abdul Musoke – Director
Abdul is a corporate strategist with expertise in market expansion, regulatory oversight and financial structuring. As Chief Strategy Officer at Afri Digital Media Corp, he leads strategic acquisitions and regulatory compliance across Africa. He also serves as Director at Albertine Nuts Uganda Ltd, overseeing finance and partnerships for a 500-acre macadamia orchard. Abdul’s experience in regulatory economics, M&A, and multinational negotiations will be instrumental in guiding Allied’s global expansion and operational scale-up.
-
Michael Moses – Chief Executive Officer
Michael has played a pivotal role in establishing Allied’s long-term strategy and commercializing its medical cannabis products, laying a strong foundation for the business’ next phase of growth. As Chief Business Development Officer, he launched the Company’s commercial arm, rolled out the sales strategy, built the client pipeline and secured multi-year partnerships in key medical markets. He also led Allied’s operational restructuring, including workflow optimisation, governance and building a scalable structure to align production, sales and compliance. Michael, an experienced entrepreneur with an Engineering Masters and a background in consulting and investment management, previously founded and scaled an award-winning digital marketing B2B business.
With a seasoned leadership team in place, Allied is well-positioned to execute on its commercial strategy and existing contracts, expand into new markets and strengthen its role as a cost-efficient supplier of pharmaceutical-grade cannabis globally. The company is committed to delivering long-term shareholder value and to drive its next phase of growth.
About Allied Corp. – CLICK HERE
Allied Corp. is a Canadian cannabis supplier with its production center in Colombia. By leveraging Canadian cannabis cultivation expertise and Colombian price advantages, Allied offers consistent supply of premium cannabis product at scale and at attractive prices, meeting international high-quality standards.
Investor Relations :
Disclaimer and Forward-Looking Statements:
No regulatory authority assumes responsibility for the accuracy or adequacy of this release.
This press release includes certain statements that may be deemed "forward-looking statements" under U.S. and Canadian securities laws. Forward-looking statements relate to Allied Corp.’s anticipated developments, strategic objectives, performance, and market opportunities. These include, but are not limited to, statements regarding Allied’s growth in Colombia, Kelowna, Nevada, and other key locations; intellectual property filings; joint development and manufacturing initiatives; and planned product introductions.
Forward-looking statements can often be identified by terms such as "anticipates," "believes," "expects," "intends," "plans," "will," "may," and similar expressions. These statements are based on current assumptions, projections, and management’s experience, but are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Notable risks include, but are not limited to, regulatory risks associated with the cannabis industry and market changes ; risks related to competition within the cannabis and medical industries; risks related to potential operational and logistical challenges; risks related to market demand; risks related to economic conditions impacting growth and profitability; risks related to potential delays or adverse changes in project locations or expansion plans; as well as other risks.
Though Allied endeavors to identify important factors that may impact actual outcomes, other unknown factors may also cause results to vary. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.
Copyright (c) 2025 TheNewswire - All rights reserved.
